Heart safety study of relugolix vs leuprolide for prostate cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial compares two hormone therapy combinations for men with prostate cancer that hasn't spread. The goal is to see if a newer oral medication (Relugolix) plus abiraterone works better than the standard injectable therapy (Lupron) plus abiraterone, while also checking heart safety.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a man 18 years or older.
- Your prostate cancer has not spread to other parts of the body (non-metastatic).
- You are planning to have radiation therapy to your prostate (often with a curative goal).
- You are willing to take a combination of hormone therapy and an oral medication for up to 2 years.
- You have not had hormone therapy, chemotherapy, immunotherapy, or radiation therapy before.
- You have no history of heart bypass surgery, heart stents, pacemaker, or defibrillator.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new hormone pill called relugolix combined with radiation therapy for men with high-risk prostate cancer. The goal is to see if this combination improves treatment outcomes.
This trial tests if giving a short-term hormone pill (relugolix) before a special PSMA PET/CT scan makes the scan clearer for men with high-risk prostate cancer. It may help doctors better see where the cancer is.
This study tests whether combining a time-restricted eating plan, a heart-healthy diet, and a weight-loss medication (GLP-1 receptor agonist) can help improve heart health and weight in men with prostate cancer who are receiving hormone therapy. It aims to reduce the risk of heart problems caused by hormone treatment.
This trial compares two hormone therapies, relugolix and leuprolide, to see which one is better for your heart health in men with prostate cancer. It's for men with a specific type of prostate cancer that is not yet advanced.
This Phase 2 study compares two medicines that lower testosterone—relugolix tablets versus leuprolide injections—to see which better improves quality of life. It’s for people with prostate cancer who are starting hormone treatment and have not used similar testosterone-lowering drugs before.
This trial tests a combination of two oral drugs, relugolix and enzalutamide, in men with high-risk prostate cancer that hasn't spread to distant parts of the body. The goal is to see if this treatment can help control the cancer before or alongside local therapies like surgery or radiation.
Hear when a new Recurrent Prostate Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.